Table 1. Clinical and molecular information for CRC patients.
| Commercial samples | Clinical samples | ||
|---|---|---|---|
| gender | male | 20 (65%) | 73 (53%) |
| female | 11 (35%) | 66 (47%) | |
| age | average | 66 years | 71 years |
| range | 37–89 years | 21–90 years | |
| mutations | APC | n.a. | 6/17 (35%) |
| TP53 | n.a. | 7/17 (41%) | |
| KRAS | n.a. | 27/79 (34%) | |
| BRAF | n.a. | 10/79 (13%) | |
| MS status | MSS | n.a. | 91 (78%) |
| MSI | n.a. | 25 (22%) | |
The table summarizes the information on patients’ gender, age, common mutations (TP53, APC, KRAS, BRAF) and microsatellite (MS) status of the tumors (MSS: microsatellite stable; MSI: microsatellite instable) for samples obtained from commercial suppliers (n = 32 tumor and n = 21 matching normal tissue) and biobanks (n = 139 pairs of tumor and adjacent normal colon tissue); n.a. = not assessed.